Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 4;228(Suppl 1):S13-S23.
doi: 10.1093/infdis/jiad148.

Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases

Axel Finckh  1   2 , Adrian Ciurea  3 , Catherine E Raptis  4 , Andrea Rubbert-Roth  5
Affiliations

Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases

Axel Finckh et al. J Infect Dis. .

Abstract

Immune-mediated inflammatory diseases (IMIDs) are a highly heterogeneous group of diseases that share a common etiology of immune dysregulation, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, among others. It is estimated that the prevalence of IMIDs ranges between 5% and 7% in developed countries. As current management of IMIDs includes the use of immunomodulatory medications, the resulting weakened immune response can increase the risk of infection, including with SARS-CoV-2 (the causative agent of COVID-19) and reduce response to vaccination, placing these individuals at continued risk of severe outcomes from COVID-19. In this article, we summarize the current literature related to COVID-19 outcomes and the immunogenicity and reactogenicity of COVID-19 mRNA vaccination among patients with rheumatologically dominated IMIDs, as well as the effect of immunomodulatory therapies on these outcomes. We conclude by providing current COVID-19 vaccination recommendations for individuals with IMID.

Keywords: COVID-19; SARS-CoV-2; immune-mediated inflammatory disease; mRNA; musculoskeletal; rheumatoid; vaccination; vaccine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. A. F. has received honoraria for lectures from AstraZeneca and Pfizer outside the submitted work. A. R. R. reports honoraria for consultation and lectures from Abbvie, Amgen, Pfizer, Galapagos, Novartis, Janssen, Eli-Lilly, Sanofi, UCB and BMS outside the submitted work. The other authors declare that the research was conducted in the absence of any commercial or financial relationship that could be regarded as a potential conflict of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol 2021; 21:680–6. - PMC - PubMed
    1. David T, Ling SF, Barton A. Genetics of immune-mediated inflammatory diseases. Clin Exp Immunol 2018; 193:3–12. - PMC - PubMed
    1. Kuek A, Hazleman BL, Östör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007; 83:251–60. - PMC - PubMed
    1. Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med 2021; 385:628–39. - PubMed
    1. Curtis JR, Johnson SR, Anthony DD, et al. . American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatol 2023; 75:E1–E16. - PMC - PubMed